ALKS 2680 clinical trials
ALKS 2680 is named as an intervention in 2 current clinical trials in our USA, France, Spain, Italy, Netherlands, Belgium, Czechia and Australia registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Alkermes, Inc. The most-studied condition is Idiopathic Hypersomnia. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Patient leaflets for ALKS 2680
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of ALKS 2680
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683 · Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
|
Phase 2/3 | Recruiting | Alkermes, Inc | USA, France, Spain, Italy, Netherlands, Belgium, Czechia, Australia |
|
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
NCT06843590 · Idiopathic Hypersomnia
|
Phase 2 | Active, closed | Alkermes, Inc | USA, France, Spain, Italy, Netherlands, Belgium, Czechia, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
ALKS 2680 in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing ALKS 2680. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-524711-36-00 · Nervous System Diseases
|
Phase 3 | Ongoing | Alkermes Inc | Sweden, Finland, Belgium + 8 more |
Conditions studied with ALKS 2680
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Alkermes, Inc | 2 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about ALKS 2680 trials
How many clinical trials are testing ALKS 2680?
2 current trials in our USA, France, Spain, Italy, Netherlands, Belgium, Czechia and Australia registers name ALKS 2680 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are ALKS 2680 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Czechia and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors ALKS 2680 clinical trials?
The lead sponsor is Alkermes, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ALKS 2680 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ALKS 2680 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ALKS 2680 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.